Morphic News

Morphic to Participate in RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today

GlobeNewswire04:05

Morphic Ethical Continues Share Buy-Back

TipRanksMay 9 07:57

Morphic Fund Advances Share Buy-Back Effort

TipRanksMay 7 08:18

Morphic Ethical Fund Continues Stock Buy-Back

TipRanksMay 6 08:47

Future Generation's Holdings Decrease in Morphic Fund

TipRanksMay 3 14:48

Morphic Fund Reports Change in Major Shareholder

TipRanksMay 3 14:48

Morphic Ethical Fund Continues Share Buy-Back

TipRanksMay 3 08:18

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Yahoo FinanceMay 1 19:32

Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Accolade (ACCD) and Morphic Holding (MORF)

TipRanksApr 30 14:21

Morphic Fund Completes Share Buy-Back

TipRanksApr 29 16:07

Morphic Holding Launches New Stock Offering, Ends Previous Deal

TipRanksApr 27 05:43

Morphic Holding Files Automatic Mixed Shelf

Seeking AlphaApr 27 05:34

Stifel Nicolaus Remains a Hold on Morphic Holding (MORF)

TipRanksApr 26 19:52

Morphic Holding (MORF) Gets a Buy From RBC Capital

TipRanksApr 26 18:36

Morphic Holding's Buy Rating Affirmed: Promising Trials and Strong Financial Outlook

TipRanksApr 26 17:22

Morphic Holding (MORF.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $521,000; earnings per share of -0.91 dollars, previous value of -0.90 dollars, expected value of -0.93 dollars.

Morphic Holding (MORF.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $521,000; earnings per share of -0.91 dollars, previous value of -0.90 dollars, expected value of -0.93 dollars.

Zhitong FinanceApr 25 21:42

Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review

Yahoo FinanceApr 25 20:37

Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027

Morphic Therapeutic Ended First Quarter With $658.8M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into Second Half Of 2027

BenzingaApr 25 19:31

Morphic Holding Q1 2024 GAAP EPS $(0.91) Beats $(0.94) Estimate

Morphic Holding (NASDAQ:MORF) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(0.94) by 3.19 percent. This is a 1.11 percent decrease over losses of $(0.90

BenzingaApr 25 19:31

Press Release: Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr.

Dow JonesApr 25 19:01